Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia.
AUC
Case fatality
Comorbidities
Disease severity
Hospitalization
ICU-admission
Key parameters
Laboratory findings
Risk factors
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
17 Dec 2022
17 Dec 2022
Historique:
received:
20
03
2022
accepted:
13
12
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
21
12
2022
Statut:
epublish
Résumé
Patients' race and ethnicity may play a role in mortality from Covid-19. Studies in China, the US, and Europe have been conducted on the predictors of Covid-19 mortality, yet in the EMR countries, such studies are scarce. Therefore, we aimed to describe the hospitalization rate, ICU-admission, and in-hospital mortality of Covid-19 and predictors of in-hospital mortality in Saudi Arabia. E-medical records were examined for all Covid-19 patients diagnosed in five tertiary hospitals affiliated with the Saudi-National Guard-Health Affairs during March 21, 2020, and September 12, 2021, based on a positive SARS-CoV-2 RT-PCR test, (n = 35,284). Data were collected on patients' characteristics, comorbidities, laboratory findings, hospitalization, ICU admission, and in-hospital and overall mortality. Logestic regressions were used to identify the independent predictors of in-hospital mortality. The best laboratory parameters cut-off values to predict in-hospital mortality were identified using the area under the receiver operating characteristic curve (AUC). Significance was considered at p < 0.05. Of all 35,284 Covid-19 patients, 81.8% were adults and 21.7% were hospitalized. Compared to non-hospitalized patients, hospitalized patients were more of female gender (52.1% versus 47.3%, p < 0.001) and had higher mean age (p < 0.001), higher mean BMI (p < 0.001), and higher rates of: diabetes (p < 0.001), hypertension (p < 0.001), ischemic heart disease (p < 0.001), cancer (p < 0.001), COPD (p < 0.001) and asthma (p = 0.011). The study showed 3.1% overall case-fatality, 20.3% ICU admission rate, and 9.7% in-hospital mortality. Predictors of in-hospital mortality among adult patients were; patients' age ≥ 70 years (OR = 6.93, 95% CI 1.94-24.79), ischemic heart disease (OR = 1.80, 95% CI 1.05-3.09), ICU admission (OR = 24.38, 95% CI 15.64-38.01), abnormal C-reactive protein "CRP" (OR = 1.85, 95% CI 1.08-3.16), abnormal D-dimer (OR = 1.96, 95% CI 1.15-3.36), lymphopenia (OR = 2.76, 95% CI 2.03-3.3.76), high neutrophil count (OR = 2.10, 95% CI 1.54-2.87), and abnormal procalcitonin (OR = 3.33, 95% CI 1.88-5.90). The best laboratory parameters cut-off values to predict in-hospital mortality were CRP > 72.25 mg/L (AUC = 0.64), D-dimer > 1125 µg/L (AUC = 0.75), neutrophils count > 5,745 × 10^9/L (AUC = 0.70), lymphocytic count < 1.10 × 10^9/L (AUC = 0.72), and procalcitonin > 0.18 ng/mL (AUC = 0.76). Rates of hospitalization, ICU-admission, in-hospital mortality and overall case fatality were nearly comparable to the rates in western countries. Early interventions are necessary for high-risk Covid-19 patients, especially elderly patients and those with cardiac diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Patients' race and ethnicity may play a role in mortality from Covid-19. Studies in China, the US, and Europe have been conducted on the predictors of Covid-19 mortality, yet in the EMR countries, such studies are scarce. Therefore, we aimed to describe the hospitalization rate, ICU-admission, and in-hospital mortality of Covid-19 and predictors of in-hospital mortality in Saudi Arabia.
METHODS
METHODS
E-medical records were examined for all Covid-19 patients diagnosed in five tertiary hospitals affiliated with the Saudi-National Guard-Health Affairs during March 21, 2020, and September 12, 2021, based on a positive SARS-CoV-2 RT-PCR test, (n = 35,284). Data were collected on patients' characteristics, comorbidities, laboratory findings, hospitalization, ICU admission, and in-hospital and overall mortality. Logestic regressions were used to identify the independent predictors of in-hospital mortality. The best laboratory parameters cut-off values to predict in-hospital mortality were identified using the area under the receiver operating characteristic curve (AUC). Significance was considered at p < 0.05.
RESULTS
RESULTS
Of all 35,284 Covid-19 patients, 81.8% were adults and 21.7% were hospitalized. Compared to non-hospitalized patients, hospitalized patients were more of female gender (52.1% versus 47.3%, p < 0.001) and had higher mean age (p < 0.001), higher mean BMI (p < 0.001), and higher rates of: diabetes (p < 0.001), hypertension (p < 0.001), ischemic heart disease (p < 0.001), cancer (p < 0.001), COPD (p < 0.001) and asthma (p = 0.011). The study showed 3.1% overall case-fatality, 20.3% ICU admission rate, and 9.7% in-hospital mortality. Predictors of in-hospital mortality among adult patients were; patients' age ≥ 70 years (OR = 6.93, 95% CI 1.94-24.79), ischemic heart disease (OR = 1.80, 95% CI 1.05-3.09), ICU admission (OR = 24.38, 95% CI 15.64-38.01), abnormal C-reactive protein "CRP" (OR = 1.85, 95% CI 1.08-3.16), abnormal D-dimer (OR = 1.96, 95% CI 1.15-3.36), lymphopenia (OR = 2.76, 95% CI 2.03-3.3.76), high neutrophil count (OR = 2.10, 95% CI 1.54-2.87), and abnormal procalcitonin (OR = 3.33, 95% CI 1.88-5.90). The best laboratory parameters cut-off values to predict in-hospital mortality were CRP > 72.25 mg/L (AUC = 0.64), D-dimer > 1125 µg/L (AUC = 0.75), neutrophils count > 5,745 × 10^9/L (AUC = 0.70), lymphocytic count < 1.10 × 10^9/L (AUC = 0.72), and procalcitonin > 0.18 ng/mL (AUC = 0.76).
CONCLUSIONS
CONCLUSIONS
Rates of hospitalization, ICU-admission, in-hospital mortality and overall case fatality were nearly comparable to the rates in western countries. Early interventions are necessary for high-risk Covid-19 patients, especially elderly patients and those with cardiac diseases.
Identifiants
pubmed: 36526994
doi: 10.1186/s12879-022-07945-8
pii: 10.1186/s12879-022-07945-8
pmc: PMC9758036
doi:
Substances chimiques
Procalcitonin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
950Informations de copyright
© 2022. The Author(s).
Références
BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
Intensive Care Med. 2019 Jun;45(6):757-769
pubmed: 30888440
J Infect Public Health. 2022 Jan;15(1):13-20
pubmed: 34861603
Int J Surg. 2020 May;77:206-216
pubmed: 32289472
Lancet Digit Health. 2020 Oct;2(10):e516-e525
pubmed: 32984797
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Diagnosis (Berl). 2020 May 26;7(2):91-96
pubmed: 32352401
J Med Virol. 2020 Jun;92(6):568-576
pubmed: 32134116
J Infect Dev Ctries. 2020 Feb 29;14(2):125-128
pubmed: 32146445
Am J Emerg Med. 2021 Jul;45:290-296
pubmed: 33041130
Biomark Med. 2020 Jul;14(10):827-837
pubmed: 32490680
Chin Med J (Engl). 2003 Jul;116(7):985-7
pubmed: 12890367
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
Saudi Med J. 2020 Nov;41(11):1217-1226
pubmed: 33130842
BMC Infect Dis. 2022 Mar 30;22(1):273
pubmed: 35351028
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
BMC Infect Dis. 2020 Jun 23;20(1):445
pubmed: 32576139
J Infect. 2020 Aug;81(2):e59-e61
pubmed: 32353384
BMC Infect Dis. 2020 Sep 29;20(1):719
pubmed: 32993538
BMJ Glob Health. 2022 May;7(5):
pubmed: 35618305
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Indian J Med Res. 2013 Nov;138(5):595-608
pubmed: 24434315
Arch Gerontol Geriatr. 2021 Jul-Aug;95:104383
pubmed: 33676091
BMJ Open. 2020 Sep 17;10(9):e038976
pubmed: 32948572
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
Saudi Med J. 2020 Sep;41(9):907-915
pubmed: 32893272
J Multidiscip Healthc. 2021 Apr 15;14:839-852
pubmed: 33883900
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Chest. 2010 Sep;138(3):568-77
pubmed: 20435656
Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153
pubmed: 32455147
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Science. 2021 May 28;372(6545):
pubmed: 33906968
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
Int J Gen Med. 2020 Nov 17;13:1157-1165
pubmed: 33244256
Saudi Pharm J. 2021 Jul;29(7):682-691
pubmed: 34400862
J Med Virol. 2020 Oct;92(10):1759-1760
pubmed: 32275075
Pharmacol Res. 2020 Aug;158:104931
pubmed: 32446978
J Epidemiol Glob Health. 2021 Mar;11(1):98-104
pubmed: 33095982
Intern Med J. 2020 Dec;50(12):1483-1491
pubmed: 33022124
J Infect Public Health. 2021 Aug;14(8):994-1000
pubmed: 34153731
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Obesity (Silver Spring). 2020 Jun;28(6):1005
pubmed: 32237206
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Ann Hematol. 2020 Jul;99(7):1421-1428
pubmed: 32495027
PLoS One. 2020 Nov 12;15(11):e0242127
pubmed: 33180830
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
J Infect Public Health. 2021 Jun;14(6):717-723
pubmed: 34020211
BMC Infect Dis. 2022 Feb 8;22(1):136
pubmed: 35135491
J Infect Public Health. 2022 Jan;15(1):142-151
pubmed: 34764042
Aging Dis. 2019 Apr 1;10(2):367-382
pubmed: 31011483
BMC Med. 2014 Apr 10;12:61
pubmed: 24722122
Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1:S27-36
pubmed: 22701840
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
Health Sci Rep. 2022 May 05;5(3):e628
pubmed: 35539445
Ann Transl Med. 2021 Feb;9(3):201
pubmed: 33708828
Clin Chem Lab Med. 2020 Jun 25;58(7):1095-1099
pubmed: 32301746
J Leukoc Biol. 2017 Oct;102(4):977-988
pubmed: 28733462